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Stella Santarone,1 Joseph Pidala,2 Marta Di Nicola,1 Teresa Field,2 Melissa Alsina,2
Ernesto Ayala,2 William Janssen,2 Mohamed A. Kharfan-Dabaja,2 Leonel Ochoa,2 Lia Perez,2
Janelle Perkins,2 Jyoti Raychaudhuri,2 Hugo Fernandez,2 Claudio Anasetti2We aimed to evaluate the safety and efficacy of fludarabine (FLU) and pharmacokinetic-targeted busulfan
(BU) as conditioning regimen for hematopoietic cell transplantation (HCT) in adult patients with acute lym-
phoid leukemia (ALL). Forty-four patients with ALL (27 in first complete remission [CR1] and 17 in more
advanced disease stage: 4 with primary induction failure [PIF], 12 in CR2, and 1 in CR3) received FLU and
pharmacokinetic-targeted BU as preparative therapy for HCT. Grafts were T-replete, filgrastim-mobilized
peripheral blood stem cells (PBSC). Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus
(TAC) and short-course methotrexate in 36 patients, TAC and sirolimus in 3, and TAC and mycophenolate
mofetil in 5. Primary engraftment was achieved in all 44 patients. The cumulative incidence of transplant-
related mortality (TRM) was 2% (95% confidence interval [CI] 0%-16%) at 100 days and 18% (95% CI
10%-34%) at 2 years. The 2-year cumulative incidence of relapse was 19% (95% CI 8%-41%) for those trans-
planted in CR1, and 48% (29%-80%) for those with more advanced disease. After a median follow-up of 32
months (range: 15-69 months), the 2-year overall survival (OS) was 54% (95% CI 39%-69%). Relapse-free
survival (RFS) at 2 years was 63% (95% CI 45%-81%) for patients transplanted in CR1 and 34% (95% CI
11%-57%) for patients transplanted in more advanced disease. When compared to irradiation-containing
regimens, FLU and PK-targeted BU appear safer and similarly effective in controlling ALL, providing a treat-
ment option for adult patients with ALL.
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Advances in the intensified chemotherapeutic reg-
imens of adult acute lymphoblastic leukemia (ALL)
have greatly improved patient outcome and survival
in the last decades. Over 90% of adults with ALL
achieve complete remission (CR), but most experience
relapse, and the 5-year survival is only 25% to 40% [1]
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6/j.bbmt.2011.02.011to chemotherapy for patients with ALL [2], but in
adults over 35 years the benefits from HCT antileuke-
mia effects are offset from the high transplant-related
mortality (TRM) [3]. Reduced-intensity conditioning
(RIC) regimens offer the opportunity for safer trans-
plantation in older adults, but dose intensity remains
important to prevent leukemia relapse after HCT
[4]. For example, with a very low-intensity regimen
of fludarabine (FLU) plus 200 cGy total body irradia-
tion (TBI), the relapse rate was 24% per year in adults
transplanted in first remission [5]. Busulfan (BU) is as
potent in inducing apoptosis of primary ALL cells as it
is in acute myeloid leukemia (AML) cells [6]. Marrow
ablative doses of BU combined with FLU have been
extremely well tolerated in older adults [7-10].
However, a randomized trial in children with ALL
found that conditioning with BU administered based
on weight or body surface area leads to lower
survival compared to TBI [11]. As there is broad vari-
ation in BU clearance in children and adults, individu-
alized BU dosing based on pharmacokinetic (PK)
parameters is expected to decrease rejection, relapse,1505
1506 Biol Blood Marrow Transplant 17:1505-1511, 2011S. Santarone et al.and toxicity [12-15]. Based on these considerations, we
have adopted a FLU/BU regimen with PK-guided
dose adjustments as conditioning regimen for ALL pa-
tients undergoing HCT. Here, we report the results in
44 adult patients.
PATIENTS AND METHODS
Forty-four consecutive patients with ALL who re-
ceived conditioning with FLU/BU before an allogeneic
HCT at the Moffitt Cancer Center, Tampa, Florida,
between February 2005 and March 2009 were included
in this report. All patients provided informed consent
for follow-up, and were part of a retrospective study
of the FLU/BU regimen approved by the University
of South Florida institutional review board. Table 1
shows the patients’ characteristics. CR was defined by
standardmorphological criteria. Twenty-seven patients
with predominantly high-risk disease received HCT in
CR1, and 17 received transplants for more advanced
disease including CR2, CR3, and primary induction
failure. High-risk categorization for those in CR1 was
based on the following definitions: age $35 years; pre-
senting white blood cell count.100,000 for B cell ALL
and .30,000 for T cell phenotype ALL; and high-risk
cytogenetic abnormalities including t(9:22), t(4:11),
11q23, and t(1:19). Of these 27 CR1 patients, 2 did
notmeet any of these criteria andwere therefore consid-
ered standard risk. Of the remainder, 13 were age $35
years, 12 total (9 for B phenotype and 3 for T cell phe-
notype) met criteria for elevated presenting white blood
cell count, 13 had t(9:22), 1 had t(4:11), and 1 had
11q23; none had t(1:19). Sixteen of the 17 patients
with the Philadelphia (Ph) chromosome received imati-
nib (n 5 14) or dasatinib (n 52) during induction and
maintenance prior to transplant. The median duration
of tyrosine kinase inhibitor (TKI) therapy prior to
HCT for those treated was 5.8 months (range: 2.8-
11.8). Of these 16 patients, 14 were treated with TKI
following HCT with a median duration of post-HCT
therapy of 11.6 months (range: 2.4-45.3). In 2 of these
14 cases, TKI therapy was discontinued (after 16 and
8 months of TKI therapy, respectively) because of mye-
losuppression, which could not be managed with dose
reduction and supportive transfusion and growth factor
therapy.
Transplantation Procedures
Thirty-one patients received FLU/BU as standard
treatment (target BU AUC 5300 mM*min/L) and 13
patients (target BU AUC 6,000 mM*min/L in 8 cases
and 7500 mM*min/L in 5 cases) were enrolled on an
ongoing trial to assess the maximum tolerated BU
area under the concentration curve (AUC). Day
0 was the day of transplantation. The treatment con-
sisted of FLU, 40 mg/m2 infused over 30 minutes daily
on days 26 to 23, each dose immediately followed byintravenous BU, 130-180 mg/m2 over 4 hours daily on
the same days. BU PK samples were obtained on day
26 and assayed by mass spectrometry. On days 24
and23, the BU dose was adjusted to target the desired
average AUC. The median BU AUC level following
the first 2 doses in the target AUC 5300 group was
6105 mM*min/L (range: 3952-8524); for the target
AUC 6000 group, this was 6693 mM*min/L (range:
1046-11,313); finally, for the target AUC 7500 group,
this was 7856 mM*min/L (range: 7083-8904). The
median (range) total BU dose administered was
510 mg/m2 (360-704) for the AUC 5300 group,
564 mg/m2 (361-688) for the AUC 6000 group, and
720 mg/m2 (606-720) for the AUC 7500 group.
Seizure prophylaxis consisted of lorazepam 0.5 mg
orally every 6 hours from day 27 to day 0.
Donors were HLA-genotypically identical siblings
(n5 22) or unrelated volunteers (UV) (n5 22) selected
on the basis of HLA-A, -B, -C, DRB1, andDQB1 com-
patibility by high-resolution DNA typing. Twelve UV
donors were HLA-identical, 6 were mismatched for 1
antigen and 4 for 2 antigens. Twenty-two donors
were males and 22 females. Donors and patients were
sex mismatched in 23 cases (52%), with a female donor
for a male recipient in 14 cases (32%).
Grafts wereT-replete, filgrastim-mobilized periph-
eral blood stemcells (PBSCs). PBSCswereobtained fol-
lowing the Moffitt institutional program in case of
sibling donors or through the National Marrow Donor
program in case of UV. The PBSC dose was targeted to
approximately 5.0  106 CD341 cells/kg patient body
weight. PBSCs were infused on day 0 without further
manipulation. The median dose of CD341 and CD31
cells infused was 7.7  106/kg (range: 3-10.0) and
3.14  108/kg (range: 1.26-9.04), respectively.
All patients received tacrolimus (TAC) as graft-
versus-hostdisease (GVHD)prophylaxis for aminimum
of 6 months posttransplant. The TAC doses were ad-
justed to maintain whole-blood trough levels of 5 to
15 ng/mL. As additional posttransplant immunosup-
pressive therapy, 36 patients received methotrexate at
15 mg/m2 on day 11 and 10 mg/m2 on days 13, 16,
and 111, 5 patients received mycophenolate mofetil 1
g twice daily for 1 year, and 3 received sirolimus targeted
to 4 to 12 ng/mL in serum for 1 year. Patients trans-
planted from mismatched UV donors received either
rabbit anti-thymocyte globulin 7.5 mg/kg on days 23
to 21 (n 5 4), or visilizumab 3 mg/m2 on day 0
(n5 1) under an ongoing investigational protocol.Outcome Assessment
Neutrophil engraftment was defined as the first of
the 3 consecutive days with neutrophils more than
0.5  109/L and platelet engraftment as the first of 3
consecutive days with platelets more than 20  109/L.
Chimerism was documented by single tandem repeat
Table 1. Demographics and Clinical Data
No. of Patients*
No. of patients 44
Patient sex
Male 27
Female 17
Median age, years (range) 40 (20-57)
Age <35 18
Age $35 26
Median WBC count at diagnosis 109/L (range) 19 (2-674)
T cell immunophenotype 11
B cell immunophenotype 33
Karyotype abnormalities at diagnosis
t(9;22) 8
t(9;22) + other chromosomal abnormalities 9
Complex karyotype 4
Other abnormalities 7
None 16
Disease status at HCT
CR1 27
PIF 4
CR2 12
CR3 1
Patients with previous CNS involvement 5
Median time diagnosis to HCT, months (range) 7 (3-99)
Median time CR1 to HCT (CR1 only), months (range) 6 (3–46)
WBC indicates white blood cells; CR, complete remission; PIF, resistant
to initial remission induction; HCT, hematopoietic cell transplant; CNS,
central nervous system.
*No. of patients, except where indicated.
Biol Blood Marrow Transplant 17:1505-1511, 2011 1507HCT for Acute ALL with Targeted Busulfanpolymorphism analysis of marrow or peripheral blood
samples. Acute GVHD and chronic GVHD
(cGVHD) were graded according to standard criteria
[16,17]. Toxicity was scored using the Common
Toxicity Criteria version 3.0 (NCI, Bethesda, MD).
TRM was defined as death because of any cause
other than leukemia relapse. Event-related data were
measured from the date of transplantation to that of
death from any cause in the case of overall survival
(OS) and from the date of transplantation to that of
disease relapse or death from any cause in the case of
relapse-free survival (RFS).Statistical Analysis
All qualitative factorswere summarized as frequency
and percentage, and all quantitative factors as median
and range. Data were analyzed as of January 24, 2011.
The Kaplan-Meier method was used to analyze OS
andRFS. Stratified survival curveswere compared using
the log-rank test. The probability of nonrelapse mortal-
ity (NRM) and leukemia relapse were evaluated apply-
ing the cumulative incidence (CI) method taking into
account competing risks. Similarly, the cumulative inci-
dence of grade 2 to 4 acute GVHD (aGVHD) andNIH
consensus criteria determined moderate-to-severe
chronic GVHD (cGVHD) were estimated [16,17],
accounting for primary disease relapse and nonrelapse
death as competing risk events. Statistical analyses
were performed utilizing NCSS 2007 software version
7.1.20. Gray’s method was applied for comparing CI
between groups using R software [18].RESULTS
Regimen-Related Toxicity
Significant toxicity was limited only to oral muco-
sitis. Twenty-six patients (59%) experienced grade III
to IV oral mucositis, which was transient and com-
pletely reversible in all cases. No other significant
toxicity occurred. In particular, no patient was affected
by central nervous system (CNS) toxicity, veno-
occlusive disease of the liver, or idiopathic pneumonia
syndrome. Themedian duration of hospitalization was
25 days (range: 9-41).
Engraftment
All patients achieved primary sustained engraft-
ment, with a median time of 15 (range: 11-20) days
to 0.5  109/L neutrophils and 15 (range: 9-22) days
to 20 109/L platelets. There was no early or late graft
failure. At a median of 37 (range: 23-114) days post-
transplant, engraftment studies showed that 14 of 35
(40%) evaluable patients were complete (100%) donor
chimeras and 21 were mixed chimeras with a median of
100% (range: 97%-100%%) donor granulocytes and
98.5% (range: 68%-100%) donor T-lymphocytes.
Median granulocyte andT-lymphocyte donor engraft-
ment was 100% at 6 months posttransplant.
GVHD
Accounting for primary disease relapse and nonre-
lapse deaths as competing risk events, the 100-day
cumulative incidence of grade 2 to 4 aGVHD was
64% (95% CI 51%-80%). The cumulative incidence
of grade 3 to 4 aGVHD was 14% (95% CI 7%-29%).
The cumulative incidence of NIH consensus criteria
determined moderate-to-severe chronic GVHD was
21% (95% CI 12%-38%).
TRM
There was no early mortality resultant from condi-
tioning regimen–related toxicity. Nine nonrelapse
deaths occurred. Three died (days 1227, 1161, and
1255, respectively) of pneumonia and respiratory fail-
ure. One died of disseminated fungal infection on day
1113. Two died from aGVHD (1 on day153, and the
other of late aGVHD on day 1275). Three (days
1143,1312, and11084, respectively) died of unknown
etiology. The cumulative incidence estimate of NRM at
100 days was 2% (95% CI 0%-16%), 18% (95% CI
10%-34%) at 1 year, and 18% (95% CI 10%-34%) at
2 years. Two-year TRM (Figure 1) was 17% (95% CI
6%-47%) for those age\35, and 19% (95% CI 9%-
42%) for those age 35 and greater (P 5 .73). Given the
potential toxicity associated with escalating BU target
AUC among the patients in this series, we examined
NRM stratified by AUC: the 2-year NRM for AUC
5300 was 13% (95% CI 5%-32%), AUC 6000 was
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Figure 1. Cumulative incidence of nonrelapse mortality according to
age\35 (solid line) vs. age $35 (dashed line), P 5 .73.
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Figure 2. Cumulative incidence of relapse, stratified according to
remission status at time of transplant (solid line 5 CR1, dashed
line5more advanced disease, including CR2 and -3, and primary induc-
tion failure), P 5 .036 for comparison.
1508 Biol Blood Marrow Transplant 17:1505-1511, 2011S. Santarone et al.25% (95%CI 8%-83%), and AUC7500was 40% (95%
CI 14%-100%), P5 .32 for comparison. This finding is
supported by the results of prospective trial of BU dose
escalation, which demonstrates significantly increased
NRM in the AUC 7500 group [19]. These findings sug-
gest that optimal BU AUC utilizing this approach is
5300 to 6000 mM*min/L.
Leukemia Relapse
Leukemia relapse occurred in 13 patients (30%) at
a median of 122 days after transplant (range: 7-681).
The cumulative incidence estimate of leukemia relapse
at 2 years was 19% (95% CI 8%-41%) for patients
transplanted in CR1, and 48% (95% CI 29%-80%)
for those with more advanced disease (P 5 .036) at
time of transplant (Figure 2). Among the 17 patients
with Ph(1) disease, the 2-year relapse incidence was
24% (95% CI 10%-57%), and was 34% (95% CI
20%-58%) in the remaining 27 patients with Ph(2)
disease, P 5 .5 for comparison. Importantly, the ma-
jority of those with Ph(1) disease were treated with
both pre- and post-HCTTKI therapy, which contrib-
uted to disease control. Twelve patients were refrac-
tory to subsequent chemotherapy and died, whereas
1 patient was reinduced back into CR with salvage
systemic chemotherapy, and has sustained this remis-
sion for 15 months with ongoing nilotinib therapy.
Donor lymphocyte infusion was not utilized.
Survival
Twenty-three patients survive disease free after
amedian follow-up of 32months (range: 15-69months)
posttransplant. The performance status of surviving
patients at last visit was excellent with a Karnofsky
score of 90% to 100%. The 2-year estimate for OS ofall patients was 54% (95% CI 39%-69%), which
differed according to remission status at the time of
transplantation (Figure 3). The 2-year estimate of
RFS for the overall sample was 52% (95% CI 37%-
67%). RFS at 2 years was 63% (95% CI 45%-81%)
for patients transplanted in CR1 and 34% (95% CI
11%-57%) for patients transplanted in more advanced
disease (Figure 4). Among the 17 patients with Ph(1)
ALL, 10 (59%) survive disease free and 7 died (1 for
aGVHD, 2 pneumonia/respiratory failure, 1 unknown,
and 3 after leukemia relapse). Patient age, remission
status, Ph positivity, and donor type did not demon-
strate significant association with OS, and therefore
were not considered in a multivariable analysis.DISCUSSION
The majority of adults with ALL will achieve com-
plete remission after intensive induction chemother-
apy. However, most will fail on account of disease
relapse during or after consolidation and maintenance
chemotherapy. Conversely, allogeneic HCT in first
CR can provide sustained disease-free survival (DFS)
of 40% to 60%. Major randomized trials and system-
atic review and meta-analyses demonstrate the superi-
ority of HCT over non-HCT therapy in adult ALL in
first complete remission (CR1) [2,20]. As well, HCT
offers the only curative therapy in those beyond
CR1. Therefore, HCT plays an integral role in the
therapy of adult ALL.
However, the optimal conditioning regimen before
HCT for adult patients with ALL remains unknown.
TBI in combination with cyclophosphamide (CY) or
etoposide is considered standard preparative therapy
by many centers [21]. However, TBI-containing
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Figure 3. Overall survival, stratified by remission status at time of
transplant (dashed line 5 CR1, solid line 5 more advanced disease),
log-rank P 5 .06.
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Figure 4. (A) Relapse-free survival from date of transplantation, strat-
ified by remission status (dashed line5CR1, solid line5more advanced
disease), log-rank P 5 .09. (B) Relapse-free survival from date of trans-
plantation, stratified by age (solid line 5 age\35, dashed line 5 age
$35), log-rank P 5 .79.
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adverse effects. Beyond shared late effects of allogeneic
transplantation, data indicate that TBI is associated
with increased risk for cataract formation, whereas
busulfan is associatedwithgreater risk for irreversible al-
opecia [22]. Importantly, the largest randomized trial of
HCT in ALL to date has demonstrated prohibitive
TRMin thosewithhigh-riskdisease,whichundermined
the beneficial reduction in disease relapse [3]. Busulfan
has been utilized in conjunctionwith cyclophosphamide
as an alternative to TBI-containing conditioning prior
to HCT for ALL. Several retrospective comparisons
of registry data have examined outcomes after busulfan
versus TBI-based conditioning. These are heteroge-
neous in several important disease risk and transplanta-
tion variables. As well, these exclusively report the
results of oral busulfan administration without pharma-
cokinetic monitoring. Although most suggest superior
event-free survival (EFS) and lower relapse after TBI-
based conditioning [23-25], another demonstrates
comparable outcomes [26]. The only randomized
prospective trial conducted to date that comprised 43
pediatric ALLpatients demonstrated superiorEFS after
TBI-based conditioning, but comparable relapse risk
and OS [11]. In total, no high-quality evidence demon-
strates the superiority of TBI-based conditioning prior
to HCT for adult ALL, and the toxicity associated
with this historical myeloablative approach undermines
the success of HCT.
In the last decade, much effort has been made to
reduce BU regimen-related toxicity and mortality
without compromising efficacy. The use of pharmaco-
kinetic targeting of intravenous (i.v.) BU has allowed
for more precise busulfan delivery, which has resulted
in increased efficacy and reduced regimen related
toxicity. Once-daily i.v. BU in combination with
FLU has been shown to be convenient, allow consis-
tent dose-to-dose BU levels in the same patient andcomplete drug clearance between doses, and minimize
toxicities [9,10,27,28]. Although the majority of this
work has been performed in myeloid malignancies,
Russell et al. [29] have reported in a series including
28 adult ALL patients low treatment-related mortality
of 3% and encouraging 3-year projected DFS of 65%
following myeloablative daily i.v. BU, FLU, 400 CGY
TBI, and thymoglobulin.
We here report the safety and efficacy of PK-BU in
combination with FLU as conditioning regimen for
HCT in adult patients with ALL. Our results indicate
that the combination of FLU with PK-targeted BU is
well tolerated. Oral mucositis was the only significant
toxicity with a profile of incidence not different from
that observed with other conditioning regimens.
It was invariably self-limiting with no long-term
sequelae. No cases of veno-occlusive disease, CNS
toxicity, or idiopathic pneumonia syndrome were ob-
served, and no deaths resulted from regimen-related
complications. An indirect confirmation of the low
toxicity profile of our regimen is the short duration
of hospitalization (25 days ranging from 9-41 days).
All patients included in our study achieved sustained
1510 Biol Blood Marrow Transplant 17:1505-1511, 2011S. Santarone et al.engraftment with no evidence of early or late graft fail-
ure. The speed of engraftment was comparable to that
observed with other preparative regimens. We ob-
served that by day 180 after HCT our patients had
a median T-lymphocyte and myeloid cell chimerism
of 100%. TRM at 100 days and at 1 and 2 years was
2% and 18%, respectively, lower than observed in
CR1 patients with an allogeneic sibling donor re-
ported in the largest ALL trial ever performed [3],
and lower than in other published series [21,30]. Our
patients were adults, half were older than 40 years
and half had donors other than matched siblings.
Acknowledging the limitations inherent in the
small sample size and moderate follow-up period, the
preliminary results indicate encouraging disease con-
trol, and support the importance of regimen intensity
in conditioning therapy for ALL. The cumulative inci-
dence of ALL relapse post-HCT compares favorably
to that reported after the nonmyeloablative regimen
of fludarabine/200 cGY TBI [5], and RIC regimens
[31-34]. As well, the incidence of leukemia relapse
seems no higher than that observed for patients
transplanted with TBI-containing regimens; the cu-
mulative incidence of relapse reported by Goldstone
et al. [3] for ALL in CR1 was 24% in standard risk
and 37% in Ph(2) high-risk ALL. Importantly, the
majority of Ph(1) patients in this series received
a tyrosine kinase inhibitor (imatinib or dasatinib)
both prior to and after HCT, which would be expected
to contribute to disease control. Importantly, imatinib
has been safely administered as preemptive therapy or
as treatment for minimal residual disease for Ph(1)
leukemia after HCT [35]. As well, retrospective data
has demonstrated significantly reduced relapse and im-
proved DFS after HCT in Ph(1) ALL patients who
have received imatinib prior to HCT [36]. The use
of this therapy in the majority of Ph(1) patients in
our series limits comparison to historical literature
onHCT outcomes for Ph(1) ALL. Importantly, allied
literature on transplantation outcomes for ALL
demonstrate ongoing relapse and death events beyond
the follow-up period for surviving patients in our
series. Therefore, further follow-up of this cohort is
needed to discern the success of our reported condi-
tioning and transplantation approach on ALL disease
control.
When compared to TBI-containing regimens,
FLU and PK-targeted BU demonstrate reduced
NRM, but provide comparable disease control. Ulti-
mately, prospective trials are needed to elucidate the
optimal conditioning regimen in adult ALL.ACKNOWLEDGMENTS
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